ACADIA PHARMACEUTICALS INC. (ACAD) Quick Ratio
- Quick ratio · latest quarter: Value 3.06×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.06× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $1.11B ÷ $361.44M ≈ 3.06× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 1.11B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 361.44M USD | Liabilities, Current |
| Cash and equivalents | 384.99M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 571.49M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 150.64M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 108.67M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.11B | $361.44M | $384.99M | $571.49M | $150.64M | $108.67M | 3.06× |
| 2026-03-31 | $986.81M | $305.52M | $282.21M | $569.25M | $135.35M | $112.29M | 3.23× |
| 2025-12-31 | $941.14M | $277.11M | $177.69M | $641.99M | $121.46M | $111.37M | 3.40× |
| 2025-09-30 | $962.87M | $356.58M | $258.00M | $589.02M | $115.85M | $105.98M | 2.70× |
| 2025-06-30 | $869.50M | $330.02M | $253.64M | $508.36M | $107.50M | $110.53M | 2.63× |
| 2025-03-31 | $787.32M | $302.53M | $217.70M | $463.88M | $105.74M | $102.97M | 2.60× |
| 2024-12-31 | $854.73M | $394.87M | $319.59M | $436.40M | $98.74M | $91.69M | 2.16× |
| 2024-09-30 | $663.54M | $343.94M | $155.15M | $410.18M | $98.21M | $86.74M | 1.93× |
| 2024-06-30 | $604.64M | $337.85M | $177.13M | $323.81M | $103.70M | $86.07M | 1.79× |
| 2024-03-31 | $565.22M | $330.60M | $204.75M | $265.77M | $94.70M | $66.64M | 1.71× |
| 2023-12-31 | $537.13M | $254.25M | $188.66M | $250.21M | $98.27M | $40.45M | 2.11× |
| 2023-09-30 | $438.72M | $209.60M | $98.19M | $247.73M | $92.80M | $25.40M | 2.09× |
| 2023-06-30 | $457.23M | $187.94M | $107.94M | $267.44M | $81.85M | $14.12M | 2.43× |
| 2023-03-31 | $468.79M | $224.30M | $290.89M | $111.98M | $65.92M | $11.02M | 2.09× |
| 2022-12-31 | $479.02M | $125.63M | $114.85M | $301.98M | $62.20M | $11.56M | 3.81× |
| 2022-09-30 | $492.31M | $116.57M | $154.84M | $281.74M | $55.73M | $11.84M | 4.22× |
| 2022-06-30 | $504.30M | $117.68M | $139.83M | $296.52M | $67.95M | $12.53M | 4.29× |
| 2022-03-31 | $508.69M | $119.60M | $204.92M | $241.06M | $62.71M | $13.21M | 4.25× |
| 2021-12-31 | $585.07M | $96.07M | $147.44M | $373.27M | $64.37M | $14.10M | 6.09× |
| 2021-09-30 | $600.99M | $88.22M | $94.64M | $445.65M | $60.70M | $14.34M | 6.81× |
| 2021-06-30 | $608.28M | $95.33M | $266.96M | $289.96M | $51.37M | $10.79M | 6.38× |
| 2021-03-31 | $634.60M | $109.37M | $304.49M | $273.28M | $56.83M | $10.31M | 5.80× |
| 2020-12-31 | $680.21M | $105.97M | $326.03M | $305.93M | $48.25M | $9.68M | 6.42× |
| 2020-09-30 | $690.78M | $91.86M | $452.35M | $192.09M | $46.34M | $7.98M | 7.52× |
| 2020-06-30 | $702.34M | $86.42M | $310.44M | $348.11M | $43.78M | $6.21M | 8.13× |
| 2020-03-31 | $693.04M | $99.74M | $173.06M | $478.35M | $41.64M | $6.32M | 6.95× |
| 2019-12-31 | $733.21M | $74.83M | $189.68M | $507.75M | $35.78M | $6.34M | 9.80× |
| 2019-09-30 | $714.65M | $67.74M | $385.47M | $298.37M | $30.80M | $4.85M | 10.55× |
| 2019-06-30 | $413.67M | $63.81M | $74.43M | $307.45M | $31.78M | $3.82M | 6.48× |
| 2019-03-31 | $444.28M | $74.98M | $97.56M | $316.77M | $29.96M | $4.57M | 5.93× |
| 2018-12-31 | $499.61M | $59.56M | $134.76M | $338.76M | $26.09M | $4.07M | 8.39× |
| 2018-09-30 | $234.09M | $41.81M | $63.90M | $150.24M | $19.96M | $4.35M | 5.60× |
| 2018-06-30 | $282.55M | $49.21M | $74.18M | $182.67M | $25.70M | $4.74M | 5.74× |
| 2018-03-31 | $320.51M | $46.09M | $116.33M | $181.74M | $22.45M | $5.58M | 6.95× |
| 2017-12-31 | $358.69M | $49.03M | $69.42M | $271.92M | $17.34M | $5.25M | 7.32× |
| 2017-09-30 | $380.85M | $36.14M | $112.62M | $254.01M | $14.22M | $5.54M | 10.54× |
| 2017-06-30 | $428.91M | $40.91M | $143.79M | $273.53M | $11.59M | $6.00M | 10.48× |
| 2017-03-31 | $477.14M | $45.27M | $157.38M | $312.10M | $7.66M | $3.88M | 10.54× |
| 2016-12-31 | $534.94M | $42.59M | $163.62M | $365.42M | $5.90M | $4.17M | 12.56× |
| 2016-09-30 | $592.70M | $39.15M | $153.68M | $435.18M | $3.84M | $4.30M | 15.14× |
| 2016-06-30 | $412.85M | $29.02M | $131.77M | $280.78M | $293.00K | $2.87M | 14.23× |
| 2016-03-31 | (m) | $21.12M | $175.22M | $282.02M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $21.90M | $102.14M | $112.99M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $17.73M | $70.80M | $169.89M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $19.38M | $93.21M | $177.56M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $16.65M | $76.42M | $221.47M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $15.83M | $61.85M | $260.63M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $11.25M | $36.37M | $301.43M | (m) | (m) | (m) |
| 2014-06-30 | (m) | $9.34M | $13.70M | $340.75M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $8.03M | $96.45M | $272.83M | (m) | (m) | (m) |
| 2013-12-31 | (m) | $6.98M | $11.71M | $174.08M | (m) | (m) | (m) |
| 2013-09-30 | (m) | $7.87M | $11.80M | $184.38M | (m) | (m) | (m) |
| 2013-06-30 | (m) | $7.78M | $24.25M | $181.20M | (m) | (m) | (m) |
| 2013-03-31 | (m) | $5.70M | $18.44M | $83.03M | (m) | (m) | (m) |
| 2012-12-31 | (m) | $5.95M | $57.90M | $50.07M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $6.09M | $8.02M | $15.04M | (m) | (m) | (m) |
| 2012-06-30 | (m) | $6.76M | $9.21M | $12.14M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $6.43M | $5.56M | $20.37M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $6.17M | $6.89M | $24.16M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $6.41M | $8.32M | $27.83M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $5.95M | $8.02M | $32.34M | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $6.83M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $5.96M | $6.85M | $30.24M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $9.66M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $8.81M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $18.12M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $21.17M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |